Tango Therapeutics, Inc. (TNGX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $22.11
- As of
Kresmion compiles this page from TNGX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Tango Therapeutics, Inc. (TNGX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-09.
See the full TNGX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TNGX on one page. Preview it with sample data, then open it live with a free account.
Preview the TNGX dossierActive events for TNGX
- mediumEarnings below estimates
Q3-2026: Missed consensus by 8.8%, EPS $-0.39 vs $-0.3586 estimate
- high13F: funds added
3 tracked funds increased TNGX this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 13.9%, EPS $-0.37 vs $-0.3248 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +439% to TNGX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +725% to TNGX (2026Q2)
FREE, NO ACCOUNT
Every event on TNGX, as it fires
You are seeing 5 of 10 events recorded on TNGX since 2026-05-26.
The five above landed across 4 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
TNGX positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 87583X109 · 2026Q3 | $9.7M | 0.01% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TNGX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on TNGX
TNGX against its peers
TNGX's operating margin of -178.4% ranks in the 32nd percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TNGX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 62.4M USD | 270M USD | 29 | 18 |
| Gross margin | n/a | 67.9% | n/a | 10 |
| Operating margin | -178.4% | -45.3% | 32 | 16 |
| Net margin | -162.9% | -39.4% | 26 | 16 |
| Return on equity | -29.3% | -29.1% | 50 | 24 |
| 1 year | 191.7% | -2.6% | 93 | 22 |
Peers (24): LEGN, IRON, VKTX, DYN, IOVA, ELVN, XENE, VRDN, CPRX.D, GRTX.D, ZLAB, TLX, ARQT, DNLI, CELC, CRSP, ACAD, IDYA, VCEL, RLAY, IONS, ADMA, BEAM, DFTX. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TNGX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TNGX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TNGX in the last 180 days.
Upstream: SEC EDGAR filings for TNGX
Kresmion, "Tango Therapeutics, Inc. (TNGX) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/TNGX. Upstream data: SEC EDGAR filings for TNGX.
Link to this data (HTML):
<a href="https://kresmion.com/research/TNGX">Tango Therapeutics, Inc. (TNGX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TNGX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TNGX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.